In the year or so since I last looked at Exact Sciences (EXAS), quite a bit has changed and most of it for the better. While top-line data from the company's pivotal study of Cologuard didn't live up to the most bullish hopes, I believe it was more than enough for approval and commercial adoption. The company has also decided to keep its tests in-house (meaning it doesn't have to share profits with testing companies) and laid out a logical marketing strategy to target the most probable high-volume users. Last and not least, the company should have a Medicare coverage decision in hand not too long after approval and in time for the commercial launch.
Only subscribers can access this article, which is part of the PRO research library covering 3,773 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: